Diverting Ileostomy Duration Is the Main Determinant of Ileostomy-Related Complications after Surgical Treatment of Rectum Cancer
Table 1
Patient characteristics.
Characteristic
n = 133
Age, y, mean ± SD (median, range)
61.3 ± 13.5 (63, 32–87)
Male gender
82 (61.7%)
BMI (kg/m2)
27.87 ± 5.70
Preoperative condition
ASA score
1
69 (51.9%)
2
41 (30.8%)
3
19 (14.3%)
4
4 (3%)
Hemoglobin, g/dL, mean ± SD
12.6 ± 4.1
Albumin, g/dL, mean ± SD
4.1 ± 0.9
Diabetes
37 (27.8%)
Hypertension
67 (50.4%)
Tumor characteristics
Histological type
Adenocarcinoma
121 (91.0%)
Mucinous adenocarcinoma
10 (7.5%)
Signet ring cell carcinoma
1 (0.8%)
Neuroendocrine tumor
1 (0.8%)
Tumor diameter, cm (mean ± SD)
4.5 ± 1.5
Stage
I
63 (47.4%)
II
19 (14.3%)
III
44 (33.1%)
IV
7 (5.3%)
Grade
I
73 (54.9%)
II
44 (33.1%)
III
15 (12.0%)
Distance from anal verge, cm, mean ± SD
8.0 ± 2.7
Neoadjuvant treatment
No neoadjuvant treatment
63 (47.4%)
Neoadjuvant radiotherapy
26 (19.5%)
Neoadjuvant radiochemotherapy
44 (33.1%)
Neoadjuvant-surgery duration, days, mean ± SD, (median, range)
79.1 ± 42.0 (75.5, 9–201)
Adjuvant treatment
No adjuvant treatment
62 (46.6%)
Adjuvant chemotherapy
22 (16.5%)
Adjuvant radiochemotherapy
49 (36.8%)
Duration of ileostomy, days, mean ± SD, (median, range)
194.8 ± 120.0 (195, 16–670)
Unless otherwise stated, data are presented in frequency (percent). Duration between the end of neoadjuvant treatment and surgery in patients that received neoadjuvant treatment.
